Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease
Mulas, GiovannaMethodology
;Fenu, SandroConceptualization
;Carboni, EzioConceptualization
;Spiga, SaturninoConceptualization
;Carta, Anna R
Last
Project Administration
2019-01-01
Abstract
Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of the proinflammatory cytokine tumor necrosis factor α. Neuroinflammation and angiogenesis contribute to classical neuronal mechanisms underpinning the pathophysiology of l-dopa-induced dyskinesia, a motor complication associated with l-dopa therapy in Parkinson's disease. The efficacy of thalidomide and the more potent derivative 3,6'-dithiothalidomide on dyskinesia was tested in the 6-hydroxydopamine Parkinson's disease model.File | Size | Format | |
---|---|---|---|
Boi_et_al-2019-Movement_Disorders.pdf Solo gestori archivio
Description: articolo principale
Type: versione post-print
Size 6.1 MB
Format Adobe PDF
|
6.1 MB | Adobe PDF | & nbsp; View / Open Request a copy |
CartaAR_Immunomodulatory-Drugs.pdf open access
Type: versione editoriale
Size 6.14 MB
Format Adobe PDF
|
6.14 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.